Long-term prognosis in patients undergoing redo-isolated aortic valve replacement.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Future cardiology Pub Date : 2023-11-01 Epub Date: 2023-12-11 DOI:10.2217/fca-2023-0050

Aleksander Dokollari, Gianluca Torregrossa, Serge Sicouri, Matteo Cameli, Giulia Elena Mandoli, Stephanie Kjelstrom, Edvin Prifti, Altin Veshti, Massimo Bonacchi, Sandro Gelsomino

{"title":"Long-term prognosis in patients undergoing redo-isolated aortic valve replacement.","authors":"Aleksander Dokollari, Gianluca Torregrossa, Serge Sicouri, Matteo Cameli, Giulia Elena Mandoli, Stephanie Kjelstrom, Edvin Prifti, Altin Veshti, Massimo Bonacchi, Sandro Gelsomino","doi":"10.2217/fca-2023-0050","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate clinical outcomes after redo aortic valve replacement (AVR) with sutured valves, versus valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), versus sutureless valves. Methods: We identified 113 consecutive patients undergoing redo AVR with either ViV-TAVR, redo-sutured and redo-sutureless valves between August 2010 to March 2020. Heart-team made the decision whether patient should undergo redo-sutureless versus ViV-TAVR, versus redo-sutured AVR. Results: Preoperatively, redo-sutured (n = 57), ViV-TAVR (n = 31) and redo-sutureless (n = 25) patients were compared. Postoperatively, after propensity-adjustment analysis, the redo surgical aortic valve replacement group had a higher incidence of new postoperative atrial fibrillation (POAF; p = 0.04) compared with redo-sutureless group. Follow-up outcomes analysis did not show differences among groups. Conclusion: Patients undergoing redo-sutureless AVR experienced a higher incidence of POAF compared with patients undergoing redo-sutured.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":"19 14","pages":"685-694"},"PeriodicalIF":1.6000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/fca-2023-0050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate clinical outcomes after redo aortic valve replacement (AVR) with sutured valves, versus valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), versus sutureless valves. Methods: We identified 113 consecutive patients undergoing redo AVR with either ViV-TAVR, redo-sutured and redo-sutureless valves between August 2010 to March 2020. Heart-team made the decision whether patient should undergo redo-sutureless versus ViV-TAVR, versus redo-sutured AVR. Results: Preoperatively, redo-sutured (n = 57), ViV-TAVR (n = 31) and redo-sutureless (n = 25) patients were compared. Postoperatively, after propensity-adjustment analysis, the redo surgical aortic valve replacement group had a higher incidence of new postoperative atrial fibrillation (POAF; p = 0.04) compared with redo-sutureless group. Follow-up outcomes analysis did not show differences among groups. Conclusion: Patients undergoing redo-sutureless AVR experienced a higher incidence of POAF compared with patients undergoing redo-sutured.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

接受重新分离主动脉瓣置换术患者的长期预后。

目的：评估使用缝合瓣膜、瓣膜置入经导管主动脉瓣置换术（ViV-TAVR）和无缝合瓣膜重新进行主动脉瓣置换术（AVR）后的临床疗效。方法：我们确定了 2010 年 8 月至 2020 年 3 月期间接受 ViV-TAVR 重做主动脉瓣置换术、缝合瓣膜重做主动脉瓣置换术和无缝合瓣膜重做主动脉瓣置换术的 113 例连续患者。心脏团队决定患者是否应接受重做无缝合瓣膜与 ViV-TAVR 或重做缝合瓣膜 AVR。结果：术前，对重新缝合（57 人）、ViV-TAVR（31 人）和无缝合（25 人）患者进行了比较。术后，经过倾向调整分析，重做手术主动脉瓣置换术组与重做无缝线组相比，术后新发心房颤动（POAF；P = 0.04）的发生率更高。随访结果分析未显示出各组间的差异。结论与接受重新缝合手术的患者相比，接受重新缝合无缝线主动脉瓣置换术的患者发生 POAF 的几率更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.